Cognizant and Gilead extend partnership five-years for $800M

Cognizant on Monday said it has expanded its relationship with California-based Gilead Sciences’ global IT infrastructure for five more years in a deal estimated to be worth approximately $800 million.

The Teaneck-based IT company will accelerate Gilead’s digital transformation through a collaboration aimed at enabling Gilead to streamline various parts of its business with the goal of faster time to market of various medicines for life-threatening diseases, including HIV, viral hepatitis and cancer.

“Over the past three years, Cognizant has demonstrated quality delivery, adaptability and dedication to Gilead’s success,” Marc Berson, senior vice president and chief information officer at Gilead Sciences said. “Through this collaboration, Cognizant has provided critical expertise to progress our digital transformation journey while enabling stable, secure operations. This has allowed us to advance research and commercialization of transformative treatments for some of the world’s most challenging diseases. We look forward to expanding this partnership to advance to the next phases of our capability roadmap.”

Building on the company’s collaboration, Cognizant will continue to support Gilead in the following:
Enhance the internal and external client experience;
Expand cloud operations;
Digitally transform the business; and
Provide data and analytics services;

“We’re excited about this expanded partnership with Gilead, one of the pharmaceutical industry leaders in adapting advanced technologies to better deliver transformative treatments for patients world-wide,” Surya Gummadi, executive vice president and president, Cognizant Americas said. “Working together our teams will be leveraging the latest technologies from automation to cloud computing, and Generative AI to help Gilead bring its products to market faster, more efficiently, and with higher customer satisfaction.”